在患有慢性淋巴细胞白血病的患者中,随着同时发生的免疫变化的自发回归
Gonzalo Blanco1,2, Edward Morris3, Jodie L Morris4
1Karches Center for Oncology Research, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.
概括
慢性淋巴细胞白血病 (CLL) 的自发回归 (SR) 涉及免疫激活,特别是单细胞和B2M. 这种罕见的事件显示了不同的阶段,表明了CLL潜在的新免疫疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 慢性淋巴细胞白血病 (CLL) 的自发回归 (SR) 是罕见的,发生在0.2%-1%的病例中.
- 虽然研究了瘤遗传学,但驱动SR的免疫机制在很大程度上是未知的.
- 了解SR可能会揭示CLL的新型治疗点.
研究的目的:
- 阐明与慢性淋巴细胞白血病 (CLL) 自发回归相关的免疫事件和动态.
- 识别回归的不同阶段及其免疫学标志物.
- 探索潜在的基于免疫的机制,在CLL中是SR的基础.
主要方法:
- 对患者的病例系列观察,这些患者经历了CLL的自发回归.
- 监测周围血液中CLL细胞数量,腺病,单细胞数量,B2M水平和血清IgG频段.
- 在自发回归 (SR) 和持续回归 (PR) 阶段免疫事件的特征.
主要成果:
- 确定了一个SR阶段,其特点是>99%的CLL细胞减少,腺病症解脱,单细胞增加,高B2M,和基克隆IgG带.
- 描述了随后持续回归 (PR) 阶段,维持了≥17个月.
- 观察到单细胞和B2M在SR中起作用,可能与免疫激活有关.
结论:
- 在CLL中SR涉及特定的免疫事件,包括单细胞和B2M的作用.
- 基克隆IgG带的持久性表明恶性细胞分化或正常的B细胞抗瘤反应.
- 这些发现暗示了恶性细胞消除的免疫和分子机制,可能引导新的CLL免疫疗法.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Cells of the Adaptive Immune Response
979
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
979
Disorders of Leukocytes
935
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
935
T Cell Types and Functions
998
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
998


